Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Chief Financial Officer | January 30, 2026 | January 30, 2026 |
| SOPHIRIS BIO INC.SPHS · Entity 152909 | Chief Financial Officer | December 19, 2019 | December 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date January 30, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2036-01-29 | Direct | 192,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 192,000 · Balance 192,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.
SOPHIRIS BIO INC.
Report date December 19, 2019 · Filed December 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2029-12-18 | Direct | 103,000 |
Reported balance
After 2019-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-19 · Grant · Acquired 103,000 · Balance 103,000 F1: 33% of the shares subject to the option shall vest one year after the date of grant. The remainder shall vest monthly thereafter over the next two years until fully vested on December 19, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 33% of the shares subject to the option shall vest one year after the date of grant. The remainder shall vest monthly thereafter over the next two years until fully vested on December 19, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Jan 30, 2026 21:57 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 192,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001437749-26-002578 · rdgdoc.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,000 Underlying: Class A Common Stock · 192,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service. Read SEC document |
| January 31, 2025 Filed Jan 31, 2025 21:40 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001437749-25-002435 · rdgdoc.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2035-01-30 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026 and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:58 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018625 · rdgdoc.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 16:13 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantCommon Stock (Right to Buy) · Derivative | 103,000 | $0.36 Strike: $0.36 | $37,080.00 |
DisclosureSEC source: 0001209191-19-061781 · doc4.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 103,000 shares Expires 2029-12-18 F1 · derivative.exercise_date: 33% of the shares subject to the option shall vest one year after the date of grant. The remainder shall vest monthly thereafter over the next two years until fully vested on December 19, 2022. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:28 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantCommon Stock (Right to Buy) · Derivative | 205,667 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-19-000970 · doc4.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,667 Underlying: Common Stock · 205,667 shares Expires 2028-12-30 F1 · derivative.exercise_date: 33% of the shares subject to the option shall vest on December 21, 2019. The remainder shall vest monthly thereafter over the next two years until fully vested on December 21, 2021. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 16:23 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantCommon Stock (Right to Buy) · Derivative | 12,768 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001209191-17-064705 · doc4.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,768 Underlying: Common Stock · 12,768 shares Expires 2027-12-05 F1 · derivative.exercise_date: 33% of the shares subject to the option shall vest one year after the date of grant. The remainder shall vest monthly thereafter over the next two years until fully vested on December 6, 2020. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 16:10 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantCommon Stock (Right to Buy) · Derivative | 154,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-16-154380 · doc4.xml · derivative · entry 1 Slover Peter T · CIK 0001468012 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,000 Underlying: Common Stock · 154,000 shares Expires 2026-12-06 F1 · derivative.exercise_date: 33% of the shares subject to the option shall vest one year after the date of grant. The remainder shall vest monthly thereafter over the next two years until fully vested on December 7, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.